Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

Camurus faces USFDA rejection on Acromegaly drug CAM2029

MD Bureau23 Oct 2024 4:21 PM IST

The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly.

Novo Nordisks Wegovy, Fiasp, Ryzodeg Injectables Stolen During Transit, DCGI Issues Alert

Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds

MD Bureau23 Oct 2024 3:29 PM IST

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.

Eli Lilly reports strong response for Mounjaro in India

NHS to Block Eli Lilly's Alzheimer's Drug Donanemab Over Cost Concerns: Report

MD Bureau23 Oct 2024 2:43 PM IST

The National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule that it is too expensive

Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59

MD Bureau23 Oct 2024 2:37 PM IST

The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were...

Delhi HC Cancels UNKIND Trademark, Upholds Mankind Pharmas KIND Family Rights

Mankind Pharma CALDIKIND-P gets Delhi HC protection from lookalike CALIKA-P

Farhat Nasim22 Oct 2024 6:05 PM IST

New Delhi: In relief to Mankind Pharma, the Delhi High Court has prohibited Sanshiv Health Tech from marketing its product CALIKA-P as it found the...

Eli Lilly sues vendors for selling copy of its popular weight loss drug Zepbound

MD Bureau22 Oct 2024 3:12 PM IST

Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain...

Alembic Pharma gets USFDA nod to Diltiazem Hydrochloride ER Capsules to treat hypertension

MD Bureau22 Oct 2024 2:20 PM IST

Mumbai: Drug maker Alembic Pharmaceuticals Ltd has recently announced that it has received final approval from the United States Food and Drug...

Sanofi's Opella sale faces political backlash amid fears of drug shortages

MD Bureau22 Oct 2024 10:15 AM IST

Paris: French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund...

Sanofi Rilzabrutinib earns orphan designation in EU for IgG4 related disease

Sanofi, CD&R in exclusive talks over sale of USD17 billion Opella

MD Bureau22 Oct 2024 10:00 AM IST

Sanofi said its Opella business has been valued at around 16 billion euros (USD17.38 billion), or 14 times EBITDA in 2024

India's Bioeconomy surges to USD 150 billion, but innovation gaps remain, says BIRAC MD

MD Bureau22 Oct 2024 9:30 AM IST

BIRAC MD highlighted India's significant contributions to global healthcare, with 40 percent of the world's generic drugs being supplied by Indian...

Lupin names Claus Jepsen as President, Global Specialty

MD Bureau21 Oct 2024 6:22 PM IST

Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.

Vaccine Maker to Film Maker: Serum's Adar Poonawala to invest in Karan Johar's production company

MD Bureau21 Oct 2024 3:31 PM IST

Serene Productions has entered into a binding agreement to invest Rs 1,000 crore in production house Dharma Productions and Dharmatic Entertainment...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok